172478-01-2

Basic information

• Product Name: 3-N-BOC-3-(METHYLAMINO)PIPERIDINE
• Synonyms: 3-N-BOC-3-N-METHYLAMINO PIPERIDINE;3-N-BOC-3-(METHYLAMINO)PIPERIDINE;METHYL-PIPERIDIN-3-YL-CARBAMIC ACID TERT-BUTYL ESTER;tert-butyl methyl(piperidin-3-yl)carbamate;3-(N-Boc-N-methyl)aminopiperidine;3-Boc-3-MethylaMinopiperidine;3-N-Boc-3-(MethylaMino)pi...;tert-butyl N-methyl-N-(piperidin-3-yl)carbamate
• CAS NO: 172478-01-2
• Molecular Formula: C₁₁H₂₂N₂O₂
• Molecular Weight: 214.3
• Product Categories: Amines;Pyrans, Piperidines &Piperazines;Pyrans, Piperidines & Piperazines
• Mol File: 172478-01-2.mol

Chemical Properties

• Boiling Point: 287.863 °C at 760 mmHg
• Flash Point: 127.895 °C
• Appearance: /
• Density: 1.019 g/cm³
• Vapor Pressure: 0.00242mmHg at 25°C
• Refractive Index: 1.485
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.74±0.10(Predicted)
• CAS DataBase Reference: 3-N-BOC-3-(METHYLAMINO)PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-N-BOC-3-(METHYLAMINO)PIPERIDINE(172478-01-2)
• EPA Substance Registry System: 3-N-BOC-3-(METHYLAMINO)PIPERIDINE(172478-01-2)

Safety Data

• Hazardous Substances Data: 172478-01-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-N-BOC-3-(Methylamino)piperidine is used as an intermediate compound for the synthesis of various pharmaceuticals. Its presence of a methylamino group and a BOC protecting group allows for the creation of a wide range of derivatives with potential therapeutic applications.
Used in Organic Synthesis:
3-N-BOC-3-(Methylamino)piperidine is used as a building block in the synthesis of complex organic molecules. The BOC protecting group can be selectively removed under mild conditions, enabling the formation of amines and other functional groups in a controlled manner.
Used in Research and Development:
3-N-BOC-3-(Methylamino)piperidine is used as a research compound for studying the properties and reactivity of piperidine derivatives. Its unique structure allows chemists to explore new reaction pathways and develop novel synthetic strategies.

InChI:InChI=1/C11H22N2O2/c1-11(2,3)15-10(14)13(4)9-6-5-7-12-8-9/h9,12H,5-8H2,1-4H3

Upstream product

• 18364-47-1 N-methyl-N-(3-pyridyl)amine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 406213-47-6 3-t-butoxycarbonylaminopiperidin-1-carboxylic acid benzyl ester 
• 74-88-4 methyl iodide 
• 1279817-03-6 pyridin-3-ylmethyl-carbamic acid tert-butyl ester 
• 60717-45-5 1-benzyl-N-methylpiperidin-3-amine 
• 40114-49-6 1-benzyl-3-piperidone 
• 172477-99-5 1-benzyl-3-<(t-butyloxycarbonyl)methylamino>-piperidine 

Downstream Products

• 172478-05-6 3-methylamino-1-propionyl-piperidine 

Relevant articles and documents

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors

High levels of Pim expression have been implicated in several hematopoietic and solid tumor cancers, suggesting that inhibition of Pim signaling could provide patients with therapeutic benefit. Herein, we describe our progress towards this goal using a screening hit (rac-1) as a starting point. Modification of the indazole ring resulted in the discovery of a series of imidazopyridazine-based Pim inhibitors exemplified by compound 22m, which was found to be a subnanomolar inhibitor of the Pim-1 and Pim-2 isoforms (IC50values of 0.024?nM and 0.095?nM, respectively) and to potently inhibit the phosphorylation of BAD in a cell line that expresses high levels of all Pim isoforms, KMS-12-BM (IC50?=?28?nM). Profiling of Pim-1 and Pim-2 expression levels in a panel of multiple myeloma cell lines and correlation of these data with the potency of compound 22m in a proliferation assay suggests that Pim-2 inhibition would be advantageous for this indication.

1,3-DIHYDROIMIDAZOLE FUSED-RING COMPOUND

The objective of this invention is to provide novel compounds that show excellent DPPIV-inhibiting activity. The present invention provides compounds represented by the general formula (I), salts thereof, or hydrates thereof, [wherein,T1 stands for a monocyclic or bicyclic 4 to 12-membered heterocycle having 1 or 2 nitrogen atoms in the ring, which may have substituents; in formula (I), the following formula represents a double bond or a single bond; X3 denotes an oxygen atom or a sulfur atom; X1 denotes a C2-6 alkynyl group which may have substituents; Z1 denotes a nitrogen atom or the formula -CR3=; Z2 and Z3 each independently denote a nitrogen atom, the formula -CR1=, a carbonyl group, or the formula -NR2-; R1, R2, R3, and X2 each independently denote a C1-6 alkyl group which may have substituents, and such].

Antibacterial compounds

Bacterial protein synthesis-inhibiting compounds having formula (I) and salts, prodrugs, and salts of prodrugs thereof, processes for making the compounds and intermediates in the processes, compositions containing the compounds, and methods of using the compounds are disclosed.

Condensed imidazole derivatives

The present invention is related to compounds represented by the following formula, or salts or hydrates thereof wherein, T1 represents a 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, which is a monocyclic or bicyclic structure that may have one or more substituents; X represents a C1-6 alkyl group which may have one or more substituents, or such; Z1 and Z2 each independently represent a nitrogen atom or a group represented by the formula —CR2—; R1 and R2 independently represent a hydrogen atom, a C1-6 alkyl group which may have one or more substituents, or a C1-6 alkoxy group which may have one or more substituents, or such. These are novel compounds that exhibit an excellent DPPIV-inhibiting activity.

Monocyclic Analogues of the μ-Opioid Agonist 3,8-Diazabicyclooctanes: Synthesis, Modeling, and Activity

Several monocyclic derivatives structurally related to the μ-opioid agonist 3-cinnamyl-8-propionyl-3,8-diazabicyclooctane have been synthesized and tested in binding studies using the μ-selective 3H-DAMGO as ligand.Modeling studies have been performed on the same compounds in order to explain the observed lack of affinity towards μ-opioid receptors.